Daniel Busby
Stock Analyst at RBC Capital
(2.59)
# 2,103
Out of 5,111 analysts
6
Total ratings
66.67%
Success rate
22.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $160 → $40 | $7.56 | +429.10% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $26.43 | +66.48% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $5.94 | -15.82% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $227.45 | -40.65% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $160 → $40
Current: $7.56
Upside: +429.10%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $26.43
Upside: +66.48%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $5.94
Upside: -15.82%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $227.45
Upside: -40.65%